Multiple Myeloma - Epidemiology Forecast - 2036
Description
Multiple Myeloma Insights and Trends
Multiple Myeloma is a malignant plasma cell disorder characterized by clonal proliferation in the bone marrow, leading to end-organ damage including hypercalcemia, renal impairment, anemia, and bone lesions (CRAB features).
The exact etiology of multiple myeloma remains largely unclear; however, ongoing research has improved the understanding of how genetic alterations in DNA can drive the transformation of plasma cells into malignant cells, as DNA carries the instructions that regulate most cellular functions.
Despite therapeutic advances, disease relapse remains common due to clonal heterogeneity and evolving resistance mechanisms, maintaining the need for continuous innovation in treatment sequencing.
MRD (minimal residual disease) assessment is emerging as a critical biomarker, with increasing interest in MRD-guided treatment strategies to optimize therapy duration and improve long-term disease control.
Wider adoption of advanced diagnostics such as serum free light-chain assays, improved imaging, and molecular testing is enabling earlier detection of asymptomatic disease and increasing identification of precursor conditions like Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, thereby expanding the at-risk population for progression to symptomatic multiple myeloma.
Significant survival gains with novel therapies are transforming multiple myeloma into a chronic, manageable malignancy, resulting in a steadily increasing prevalent population.
Multiple Myeloma represents approximately 1–2% of all cancers and about 10% of hematologic malignancies worldwide. Its global incidence is rising, largely driven by aging populations and advancements in diagnostic capabilities.
Multiple Myeloma is primarily a disease of older adults, with a median diagnosis age of ~69–70 years, incidence rising sharply after 60, and higher occurrence in men than women.
Long-term survival and prolonged exposure to certain therapies are associated with a higher risk of secondary malignancies, which is becoming a relevant epidemiological consideration.
Multiple Myeloma Epidemiology forecast
2025 Symptomatic Incident Cases of Multiple Myeloma: ~ 63,200
2036 Projected Symptomatic Incident Cases of Multiple Myeloma: ~ 74,800
Multiple Myeloma Growth Rate (2026–2036): 1.5% CAGR
DelveInsight's ‘Multiple Myeloma – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the multiple myeloma, historical and forecasted epidemiology of the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Multiple Myeloma Understanding
Multiple Myeloma Overview
Multiple myeloma is the second most prevalent hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from accumulating terminally differentiated monoclonal plasma cells in the bone marrow. Multiple myeloma is a malignant disorder characterized by uncontrolled proliferation of clonal plasma cells, causing various complications leading to organ dysfunction and eventually death. It grows from a premalignant condition called monoclonal gammopathy of undetermined implication (MGUS). Common symptoms include bone pain (particularly in the spine or ribs), fatigue due to anemia, recurrent infections, and complications such as hypercalcemia and kidney dysfunction.
Further details are provided in the report.
Multiple Myeloma Diagnosis
The diagnosis of Multiple Myeloma involves a combination of clinical evaluation, laboratory testing, imaging studies, and bone marrow examination. Urine analysis, including urine protein electrophoresis (UPEP), helps detect Bence Jones proteins. A definitive diagnosis is confirmed through a bone marrow biopsy, which reveals clonal plasma cell proliferation, usually exceeding 10%. Imaging techniques such as X-rays, MRI, CT scans, or PET scans are used to identify bone lesions or disease spread. Additionally, advanced diagnostic tools like cytogenetic analysis and fluorescence in situ hybridization (FISH) are employed to assess genetic abnormalities and risk stratification. Together, these approaches help establish the diagnosis and guide treatment decisions..
Further details related to country-based variations are provided in the report.
Multiple Myeloma Epidemiology
Key Findings from Multiple Myeloma Epidemiological Analysis and Forecast
In the 7MM, the US recorded the highest number of Incident cases of multiple myeloma accounting for 34,097 cases in 2025, which are expected to continue increasing through 2036.
Among the EU4 and the UK, Germany accounted for the highest number of multiple myeloma cases, followed by the UK and Italy, whereas Spain accounted for the lowest number of cases in 2025.
In the US, the 65+ age group accounted for ~73% of multiple myeloma cases in 2025, while patients 55–64 years represented ~17%, and <54 years accounted for only ~10%.
Incident cases of multiple myeloma in the US represent a significant and gradually increasing disease burden, largely driven by an aging population and improved survival outcomes resulting from advances in therapeutic options.
The presence of a large precursor population, including MGUS and smoldering multiple myeloma, highlights a considerable latent pool of individuals at risk of progression. Over time, a proportion of these patients transition to symptomatic disease, which contributes to the sustained growth of the diagnosed multiple myeloma patient population.
Scope of the Report
The report covers a segment of a descriptive overview of multiple myeloma, explaining their causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Multiple Myeloma Patient Population Forecast
Report Key Strengths
Epidemiology-based (Epi-based) bottom-up forecasting
11-year forecast
Patient Burden trends (by geography)
FAQs
What are the disease risks, burdens, and unmet needs of multiple myeloma? What will be the growth opportunities across the 7MM concerning the patient population with multiple myeloma?
What is the historical and forecasted multiple myeloma patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Multiple Myeloma is a malignant plasma cell disorder characterized by clonal proliferation in the bone marrow, leading to end-organ damage including hypercalcemia, renal impairment, anemia, and bone lesions (CRAB features).
The exact etiology of multiple myeloma remains largely unclear; however, ongoing research has improved the understanding of how genetic alterations in DNA can drive the transformation of plasma cells into malignant cells, as DNA carries the instructions that regulate most cellular functions.
Despite therapeutic advances, disease relapse remains common due to clonal heterogeneity and evolving resistance mechanisms, maintaining the need for continuous innovation in treatment sequencing.
MRD (minimal residual disease) assessment is emerging as a critical biomarker, with increasing interest in MRD-guided treatment strategies to optimize therapy duration and improve long-term disease control.
Wider adoption of advanced diagnostics such as serum free light-chain assays, improved imaging, and molecular testing is enabling earlier detection of asymptomatic disease and increasing identification of precursor conditions like Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma, thereby expanding the at-risk population for progression to symptomatic multiple myeloma.
Significant survival gains with novel therapies are transforming multiple myeloma into a chronic, manageable malignancy, resulting in a steadily increasing prevalent population.
Multiple Myeloma represents approximately 1–2% of all cancers and about 10% of hematologic malignancies worldwide. Its global incidence is rising, largely driven by aging populations and advancements in diagnostic capabilities.
Multiple Myeloma is primarily a disease of older adults, with a median diagnosis age of ~69–70 years, incidence rising sharply after 60, and higher occurrence in men than women.
Long-term survival and prolonged exposure to certain therapies are associated with a higher risk of secondary malignancies, which is becoming a relevant epidemiological consideration.
Multiple Myeloma Epidemiology forecast
2025 Symptomatic Incident Cases of Multiple Myeloma: ~ 63,200
2036 Projected Symptomatic Incident Cases of Multiple Myeloma: ~ 74,800
Multiple Myeloma Growth Rate (2026–2036): 1.5% CAGR
DelveInsight's ‘Multiple Myeloma – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the multiple myeloma, historical and forecasted epidemiology of the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Multiple Myeloma Understanding
Multiple Myeloma Overview
Multiple myeloma is the second most prevalent hematological malignancy worldwide, with a median onset of 60 years. This incurable malignancy develops from accumulating terminally differentiated monoclonal plasma cells in the bone marrow. Multiple myeloma is a malignant disorder characterized by uncontrolled proliferation of clonal plasma cells, causing various complications leading to organ dysfunction and eventually death. It grows from a premalignant condition called monoclonal gammopathy of undetermined implication (MGUS). Common symptoms include bone pain (particularly in the spine or ribs), fatigue due to anemia, recurrent infections, and complications such as hypercalcemia and kidney dysfunction.
Further details are provided in the report.
Multiple Myeloma Diagnosis
The diagnosis of Multiple Myeloma involves a combination of clinical evaluation, laboratory testing, imaging studies, and bone marrow examination. Urine analysis, including urine protein electrophoresis (UPEP), helps detect Bence Jones proteins. A definitive diagnosis is confirmed through a bone marrow biopsy, which reveals clonal plasma cell proliferation, usually exceeding 10%. Imaging techniques such as X-rays, MRI, CT scans, or PET scans are used to identify bone lesions or disease spread. Additionally, advanced diagnostic tools like cytogenetic analysis and fluorescence in situ hybridization (FISH) are employed to assess genetic abnormalities and risk stratification. Together, these approaches help establish the diagnosis and guide treatment decisions..
Further details related to country-based variations are provided in the report.
Multiple Myeloma Epidemiology
Key Findings from Multiple Myeloma Epidemiological Analysis and Forecast
In the 7MM, the US recorded the highest number of Incident cases of multiple myeloma accounting for 34,097 cases in 2025, which are expected to continue increasing through 2036.
Among the EU4 and the UK, Germany accounted for the highest number of multiple myeloma cases, followed by the UK and Italy, whereas Spain accounted for the lowest number of cases in 2025.
In the US, the 65+ age group accounted for ~73% of multiple myeloma cases in 2025, while patients 55–64 years represented ~17%, and <54 years accounted for only ~10%.
Incident cases of multiple myeloma in the US represent a significant and gradually increasing disease burden, largely driven by an aging population and improved survival outcomes resulting from advances in therapeutic options.
The presence of a large precursor population, including MGUS and smoldering multiple myeloma, highlights a considerable latent pool of individuals at risk of progression. Over time, a proportion of these patients transition to symptomatic disease, which contributes to the sustained growth of the diagnosed multiple myeloma patient population.
Scope of the Report
The report covers a segment of a descriptive overview of multiple myeloma, explaining their causes, signs and symptoms, and pathogenesis.
Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Multiple Myeloma Patient Population Forecast
Report Key Strengths
Epidemiology-based (Epi-based) bottom-up forecasting
11-year forecast
Patient Burden trends (by geography)
FAQs
What are the disease risks, burdens, and unmet needs of multiple myeloma? What will be the growth opportunities across the 7MM concerning the patient population with multiple myeloma?
What is the historical and forecasted multiple myeloma patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
Table of Contents
296 Pages
- 1. Key Insights
- 2. Report Introduction
- 3. Executive Summary
- 4. Epidemiology Forecast Methodology
- 5. Disease Background and Overview
- 5.1. Introduction
- 5.2. Causes of Multiple Myeloma
- 5.3. Risk Factors
- 5.4. Patient-related Risk Factors
- 5.5. Signs and Symptoms
- 5.6. Pathogenesis
- 5.7. Pathophysiology
- 5.8. Diagnosis
- 5.9. Stages
- 6. Epidemiology and Patient Population
- 6.1. Key Findings
- 6.2. Assumptions and Rationale
- 6.2.1. 7MM
- 6.3. Total Incident Cases of Multiple Myeloma in the 7MM
- 6.4. Total Symptomatic Incident Cases of Multiple Myeloma in the 7MM
- 6.5. United States
- 6.5.1. Total Incident Cases of Multiple Myeloma in the United States
- 6.5.2. Total Symptomatic Incident Cases of Multiple Myeloma in the United States
- 6.5.3. Gender-specific Cases of Multiple Myeloma in the United States
- 6.5.4. Age-specific Cases of Multiple Myeloma in the United States
- 6.5.5. Transplant Eligible and Ineligible Cases in Multiple Myeloma in the United States
- 6.5.6. Total Treated Cases Across the Lines of therapies in the United States
- 6.6. EU4 and the UK
- 6.6.1. Total Incident Cases of Multiple Myeloma in EU4 and the UK
- 6.6.2. Total Symptomatic Incident Cases of Multiple Myeloma in EU4 and the UK
- 6.6.3. Gender-specific Cases of Multiple Myeloma in EU4 and the UK
- 6.6.4. Age-specific Cases of Multiple Myeloma in EU4 and the UK
- 6.6.5. Transplant Eligible and Ineligible Cases in Multiple Myeloma in EU4 and the UK
- 6.6.6. Total Treated Cases Across the Lines of therapies in EU4 and the UK
- 6.7. Japan
- 6.7.1. Total Incident Cases of Multiple Myeloma in Japan
- 6.7.2. Total Symptomatic Incident Cases of Multiple Myeloma in Japan
- 6.7.3. Gender-specific Cases of Multiple Myeloma in Japan
- 6.7.4. Age-specific Cases of Multiple Myeloma in Japan
- 6.7.5. Transplant Eligible and Ineligible Cases in Multiple Myeloma in Japan
- 6.7.6. Total Treated Cases Across the Lines of therapies in Japan
- 7. Appendix
- 7.1. Bibliography
- 7.2. Report Methodology
- 8. DelveInsight Capabilities
- 9. Disclaimer
- 10. About DelveInsight
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
